Abollo-Jiménez Fernando, Campos-Sánchez Elena, Toboso-Navasa Amparo, Vicente-Dueñas Carolina, González-Herrero Inés, Alonso-Escudero Esther, González Marcos, Segura Víctor, Blanco Oscar, Martínez-Climent José Angel, Sánchez-García Isidro, Cobaleda César
Experimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer; CSIC/ Universidad de Salamanca; Campus M. de Unamuno; Institute of Biomedical Research of Salamanca (IBSAL); Salamanca, Spain.
Centro de Biología Molecular Severo Ochoa; CSIC/Universidad Autónoma de Madrid; Campus de Cantoblanco; Madrid, Spain.
Cell Cycle. 2014;13(11):1717-26. doi: 10.4161/cc.28629. Epub 2014 Mar 25.
In hematopoietic malignancies, oncogenic alterations interfere with cellular differentiation and lead to tumoral development. Identification of the proteins regulating differentiation is essential to understand how they are altered in malignancies. Chronic myelogenous leukemia (CML) is a biphasic disease initiated by an alteration taking place in hematopoietic stem cells. CML progresses to a blast crisis (BC) due to a secondary differentiation block in any of the hematopoietic lineages. However, the molecular mechanisms of CML evolution to T-cell BC remain unclear. Here, we have profiled the changes in DNA methylation patterns in human samples from BC-CML, in order to identify genes whose expression is epigenetically silenced during progression to T-cell lineage-specific BC. We have found that the CpG-island of the ENGRAILED-2 (EN2) gene becomes methylated in this progression. Afterwards, we demonstrate that En2 is expressed during T-cell development in mice and humans. Finally, we further show that genetic deletion of En2 in a CML transgenic mouse model induces a T-cell lineage BC that recapitulates human disease. These results identify En2 as a new regulator of T-cell differentiation whose disruption induces a malignant T-cell fate in CML progression, and validate the strategy used to identify new developmental regulators of hematopoiesis.
在造血系统恶性肿瘤中,致癌性改变会干扰细胞分化并导致肿瘤发展。鉴定调节分化的蛋白质对于理解它们在恶性肿瘤中如何发生改变至关重要。慢性粒细胞白血病(CML)是一种由造血干细胞发生的改变引发的双相性疾病。由于任何造血谱系中的继发性分化阻滞,CML会进展为急变期(BC)。然而,CML演变为T细胞急变期的分子机制仍不清楚。在此,我们分析了BC-CML患者人类样本中DNA甲基化模式的变化,以鉴定在向T细胞谱系特异性急变期进展过程中其表达被表观遗传沉默的基因。我们发现,在这一进展过程中,EN2(ENGAILED-2)基因的CpG岛会发生甲基化。之后,我们证明En2在小鼠和人类的T细胞发育过程中表达。最后,我们进一步表明,在CML转基因小鼠模型中En2基因的缺失会诱导出一种重现人类疾病的T细胞谱系急变期。这些结果确定En2是T细胞分化的一种新调节因子,其破坏会在CML进展过程中诱导恶性T细胞命运,并验证了用于鉴定造血新发育调节因子的策略。